Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography enterography in active Crohn's disease

Inflammatory Bowel Diseases

Volumn 16, Issue 6, 2010, Pages 974-981

  Ahmadi, Anis ^a   Li, Qin ^b   Muller, Keith ^b   Collins, Dennis ^a   Valentine, John F ^a   Drane, Walter ^a   Polyak, Steven ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Division of Biostatistics ^*  (United States)

Author keywords

Crohn's disease; Enterography; Positron emission tomography; Small bowel

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG UPTAKE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL SURGERY; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROHN DISEASE; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED; YOUNG ADULT;

EID: 77952729735     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21153     Document Type: Article

References (35)

1. Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008;68:255-266.
2. Colombel JF, Solem CA, Sandborn WJ, et al. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut. 2006;55:1561-1567.
3. Bodily KD, Fletcher JG, Solem CA, et al. Crohn disease: mural attenuation and thickness at contrast-enhanced CT enterography-correlation with endoscopic and histologic findings of inflammation. Radiology. 2006;238:505-516.
4. Higgins PD, Caoili E, Zimmermann M, et al. Computed tomographic enterography adds information to clinical management in small bowel Crohn's disease. Inflamm Bowel Dis. 2007;13:262-268.
5. Maglinte DD. Science to practice: do mural attenuation and thickness at contrast-enhanced CT enterography correlate with endoscopic and histologic findings of inflammation in Crohn disease? Radiology. 2006;238:381-382.
6. Schraut WH. The surgical management of Crohn's disease. Gastroenterol Clin North Am. 2002;31:255-263.
7. Metser U, Even-Sapir E. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin Nucl Med. 2007; 37:206-222.
8. Sasaki M, Ichiya Y, Kuwabara Y, et al. Ringlike uptake of [18F]FDG in brain abscess: a PET study. J Comput Assist Tomogr. 1990;14: 486-487.
9. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994;35:1647-1649.
10. Roitt IM, Delves PJ. Lymphocyte activation. In: Roitt IM, ed. Essential Immunology, 10th edition. Oxford, UK: Blackwell Scientific; 2001:164-176.
11. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
12. Paik JY, Lee KH, Choe YS, et al. Augmented 18F-FDG uptake in activated monocytes occurs during the priming process and involves tyrosine kinases and protein kinase C. J Nucl Med. 2004;45:124-128.
13. Babior BM. The respiratory burst of phagocytes. J Clin Invest. 1984; 73:599-601.
14. Loffler M, Weckesser M, Franzius C, et al. High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann N Y Acad Sci. 2006;1072:379-385.
15. Meisner RS, Spier BJ, Einarsson S, et al. Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:993-1000.
16. Lemberg DA, Issenman RM, Cawdron R, et al. Positron emission tomography in the investigation of pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:733-738.
17. Osman S, Danpure HJ. The use of 2-[18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography. Int J Rad Appl Instrum B. 1992;19:183-190.
18. Louis E, Ancion G, Colard A, et al. Noninvasive assessment of Crohn's disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med. 2007;48:1053-1059.
19. Skehan SJ, Issenman R, Mernagh J, et al. 18F-fluorodeoxyglucose positron tomography in diagnosis of paediatric inflammatory bowel disease. Lancet. 1999;354:836-837.
20. Booya F, Fletcher JG, Huprich JE, et al. Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology. 2006;241:787-795.
21. Sandler RS, Jordan MC, Kupper LL. Development of a Crohn's index for survey research. J Clin Epidemiol. 1988;41:451-458.
22. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
23. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571-1578.
24. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002;123:679-688.
25. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg. 2000;231:38-45.
26. Binion DG, Theriot KR, Shidham S, et al. Clinical factors contributing to rapid reoperation for Crohn's disease patients undergoing resection and/or stricturoplasty. J Gastrointest Surg. 2007;11:1692-1698.
27. Henriksen M, Jahnsen J, Lygren I, et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol. 2007;42:602-610. (Pubitemid 46633816)
28. Florie J, Horsthuis K, Hommes DW, et al. Magnetic resonance imaging compared with ileocolonoscopy in evaluating disease severity in Crohn's disease. Clin Gastroenterol Hepatol. 2005;3:1221-1228. (Pubitemid 41797674)
29. Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707-712.
30. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426-431.
31. Chiorean MV, Sandrasegaran K, Saxena R, et al. Correlation of CT enteroclysis with surgical pathology in Crohn's disease. Am J Gastroenterol. 2007;102:2541-2550. (Pubitemid 47631798)
32. Burke JP, Mulsow JJ, O'Keane C, et al. Fibrogenesis in Crohn's disease. Am J Gastroenterol. 2007;102:439-448.
33. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553. (Pubitemid 38834038)
34. Kaplan GG, Hur C, Korzenik J, et al. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007;26:1509-1520. (Pubitemid 350178810)
35. Jaffe TA, Gaca AM, Delaney S, et al. Radiation doses from smallbowel follow-through and abdominopelvic MDCT in Crohn's disease. AJR Am J Roentgenol. 2007;189:1015-1022. (Pubitemid 350032983)